Saquinavir: Clinical Trials

33 trials of Saquinavir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

30 completed, 2 withdrawn, 1 terminated. 33 Phase 2, 4 Phase 3, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 233Completed 30, Withdrawn 2, Terminated 1
Phase 34Completed 3, Withdrawn 1
Phase 13Completed 3

Follow Saquinavir: new trials by email Literature Review of Saquinavir trials Research Report on Saquinavir

Trials (filtered) newest first · largest first

All 33 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
ritonavir, saquinavir [Invirase] - HIV Infections
Phase 2CompletedHoffmann-La Roche182008-06-012016-03-07
Pharmacokinetics of Low Dose Ritonavir
ritonavir and saquinavir - HIV Infections
Phase 1 / Phase 2CompletedThe HIV Netherlands Australia Thailand Research Collaboration202008-01-012012-04-05
Clinical Trial of CNS-targeted HAART (CIT2)
FDA Approved Antiretroviral Therapy (see list below) - HIV Infections
Phase 2 / Phase 3CompletedUniversity of California, San Diego592007-03-012014-04-23
Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)
Fosamprenavir, Saquinavir - HIV Infections
Phase 2CompletedFrench National Agency for Research on AIDS and Viral Hepatitis612005-12-012026-04-02
The Pharmacokinetic Study of Saquinavir New Tablet Formulation in HIV-infected Pregnant Women.
Saquinavir and Ritonavir - HIV Infections
Phase 1 / Phase 2CompletedRadboud University Medical Center402005-08-012020-10-19
Efficacy and Safety of SQV in Patients Who Have Chronic IDV Nephrotoxicity
Saquinavir - IDV Associated Nephrotoxicity
Phase 2CompletedThe HIV Netherlands Australia Thailand Research Collaboration302004-05-012016-02-22
The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients
Saquinavir, lopinavir, ritonavir - HIV Infections
Phase 2CompletedThe HIV Netherlands Australia Thailand Research Collaboration482004-03-012012-04-05
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
tipranavir, ritonavir, saquinavir - HIV Infections
Phase 2CompletedBoehringer Ingelheim3282003-02-182023-12-01
Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children
NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV) - HIV Infections
Phase 2 / Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)2662002-08-012021-11-05
Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects
Lopinavir/ritonavir, Saquinavir mesylate, Lamivudine/zidovudine - HIV Infections
Phase 2CompletedAbbott302002-08-012007-09-27
Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor
Amprenavir/ritonavir, Saquinavir/ritonavir - HIV Infections
Phase 2 / Phase 3CompletedAbbott162001-04-012006-07-28
Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
Amprenavir/ritonavir, Saquinavir/ritonavir, Efavirenz - HIV Infections
Phase 2CompletedAbbott242001-04-012008-04-01
Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients
Tipranavir (TPV) low dose, Tipranavir (TPV) high dose, Ritonavir low dose - HIV Infections
Phase 2TerminatedBoehringer Ingelheim791999-12-012014-09-15
Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment
Atazanavir, Ritonavir, Saquinavir - HIV Infections
Phase 2CompletedBristol-Myers Squibb1999-12-012011-05-04
Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma
indinavir sulfate, nelfinavir mesylate, paclitaxel - Sarcoma
Phase 2CompletedEastern Cooperative Oncology Group331997-12-152023-06-15
Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance
Lopinavir/ritonavir, Ritonavir, Saquinavir - HIV Infections
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)1182011-03-01
Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV
Lopinavir/ritonavir, Saquinavir - HIV Infections
Phase 1 / Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)262021-11-01
The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
Ritonavir, Nelfinavir mesylate, Efavirenz - HIV Infections
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)3002021-11-01
A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs
Saquinavir, Lamivudine, Stavudine - HIV Infections
Phase 2CompletedHoffmann-La Roche1402005-06-24
A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine
Saquinavir, Zalcitabine - HIV Infections
Phase 2CompletedHoffmann-La Roche9002005-06-24

Showing 20 of 33. Sign in to see all of them.

Conditions studied

HIV Infections (30)  ·  Acquired Immunodeficiency Syndrome (6)  ·  AIDS-Related Complex (5)  ·  AIDS Dementia Complex (1)  ·  AIDS-related Kaposi sarcoma (1)  ·  Cognitive Dysfunction (1)  ·  Hypersensitivity, Delayed (1)  ·  Sarcoma (1)  ·  Sarcoma, Kaposi (1)  ·  Viremia (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (11)  ·  Hoffmann-La Roche (5)  ·  The HIV Netherlands Australia Thailand Research Collaboration (4)  ·  Abbott (3)  ·  Boehringer Ingelheim (2)  ·  Bristol-Myers Squibb (1)  ·  Eastern Cooperative Oncology Group (1)  ·  French National Agency for Research on AIDS and Viral Hepatitis (1)  ·  Gilead Sciences (1)  ·  Glaxo Wellcome (1)  ·  Parexel (1)  ·  Radboud University Medical Center (1)  ·  University of California, San Diego (1)

Countries

United States (25)  ·  Puerto Rico (11)  ·  Canada (7)  ·  France (5)  ·  Thailand (5)  ·  Germany (4)  ·  Italy (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  Argentina (3)  ·  Brazil (2)  ·  Netherlands (2)  ·  Poland (2)  ·  Australia (1)  ·  Belgium (1)

Top investigators

Kiat Ruxrungtham, MD (3)  ·  Scott Hammer (3)  ·  Eugene Sun, M.D. (2)  ·  Andrew Wiznia, MD (1)  ·  Ann J. Melvin, MD (1)  ·  Ann J. Melvin, MD, MPH (1)  ·  Barbara A da Silva, M.D. (1)  ·  Bartlett J (1)  ·  Collier A (1)  ·  Collier AC (1)  ·  Coombs R (1)  ·  Corey L (1)  ·  Courtney Fletcher (1)

Results publications

PMID 17726714, PMID 18625762, PMID 18647794, PMID 19118378, PMID 19420019, PMID 19474478, PMID 21288774, PMID 21337357, PMID 24352352, PMID 27516476

NIH funding

2005 (1), R01MH058076 (1)